Comparison of Adverse Effects of Two SARS-CoV-2 Vaccines Administered in Workers of the University of Padova

Paola Mason; Rosario Rizzuto; Luca Iannelli; Flavio Baccaglini; Valerio Rizzolo; Andrea Baraldo; Barbara Melloni; Francesca Maffione; Camilla Pezzoli; Maria Laura Chiozza; Giampietro Rupolo; Marco Biasioli; Filippo Liviero; Maria Luisa Scapellato; Andrea Trevisan; Stefano Merigliano; Alberto Scuttari; Angelo Moretto; Bruno Scarpa

doi:10.3390/vaccines11050951

Vaccines (May 2023)

Comparison of Adverse Effects of Two SARS-CoV-2 Vaccines Administered in Workers of the University of Padova

Paola Mason,
Rosario Rizzuto,
Luca Iannelli,
Flavio Baccaglini,
Valerio Rizzolo,
Andrea Baraldo,
Barbara Melloni,
Francesca Maffione,
Camilla Pezzoli,
Maria Laura Chiozza,
Giampietro Rupolo,
Marco Biasioli,
Filippo Liviero,
Maria Luisa Scapellato,
Andrea Trevisan,
Stefano Merigliano,
Alberto Scuttari,
Angelo Moretto,
Bruno Scarpa

Affiliations

Paola Mason: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Rosario Rizzuto: Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy
Luca Iannelli: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Flavio Baccaglini: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Valerio Rizzolo: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Andrea Baraldo: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Barbara Melloni: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Francesca Maffione: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Camilla Pezzoli: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Maria Laura Chiozza: Italian Red Cross, Padua Committee, Via della Croce Rossa, 130, 35129 Padova, Italy
Giampietro Rupolo: Italian Red Cross, Padua Committee, Via della Croce Rossa, 130, 35129 Padova, Italy
Marco Biasioli: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Filippo Liviero: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Maria Luisa Scapellato: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Andrea Trevisan: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Stefano Merigliano: Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Alberto Scuttari: Central Administration, University of Padova, Via VIII Febbraio 2, 35122 Padova, Italy
Angelo Moretto: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
Bruno Scarpa: Department of Statistical Sciences, University of Padova, Via Battisti 241, 35121 Padova, Italy

DOI: https://doi.org/10.3390/vaccines11050951
Journal volume & issue: Vol. 11, no. 5
p. 951

Abstract

Read online

Introduction: In Italy, on December 2020, workers in the education sector were identified as a priority population to be vaccinated against COVID-19. The first authorised vaccines were the Pfizer-BioNTech mRNA (BNT162b2) and the Oxford-AstraZeneca adenovirus vectored (ChAdOx1 nCoV-19) vaccines. Aim: To investigate the adverse effects of two SARS-CoV-2 vaccines in a real-life preventive setting at the University of Padova. Methods: Vaccination was offered to 10116 people. Vaccinated workers were asked to voluntarily report symptoms via online questionnaires sent to them 3 weeks after the first and the second shot. Results: 7482 subjects adhered to the vaccination campaign and 6681 subjects were vaccinated with ChAdOx1 nCoV-19 vaccine and 137 (fragile subjects) with the BNT162b2 vaccine. The response rate for both questionnaires was high (i.e., >75%). After the first shot, the ChAdOx1 nCoV-19 vaccine caused more fatigue (p p p p = 0.046), fever (p p p = 0.016) than the BNT162b2 vaccine. After the second dose of the BNT162b2 vaccine, more myalgia (p = 0.033), tingles (p = 0.022), and shivers (p Conclusions: The adverse effects of both vaccines were transient and, overall, mild in severity.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords